Rejigging Merck KGaA partnership, Eliot Forster gains full control of the alpha in F-star's constellation
Eliot Forster walked into this year’s JP Morgan conference — his first since assuming the CEO seat at F-star — with a clear goal in mind: Talk to Merck KGaA about getting its lead bispecific antibody back.
Four months later, the seasoned biotech entrepreneur is pleased to find FS118 fully under his team’s control as he pivots F-star away from a partnership model into a more mature, independent player making its own calls in the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.